Immunic

IMUX

Market cap $81.8M

NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL.

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's third quarter highlights, with a particular focus on the progress of its oral MS treatment, vidofludimus calcium. Dr Vitt noted the company had a strong presence at the 2025 ECTRIMS conference, presenting important new data from several clinical studies.

Immunic Inc (NASDAQ:IMUX) highlighted positive clinical results for its lead drug candidate, vidofludimus calcium, showing statistically significant improvement in progressive multiple sclerosis (MS), as the company reported its third quarter 2025 financial results and provided a corporate update. At the 41st Congress of ECTRIMS in September, Immunic presented data from the Phase 2 CALLIPER trial, which showed a greater than two-fold probability of 24-week confirmed disability improvement versus placebo in patients with progressive multiple sclerosis (PMS).

– Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41st Congress of ECTRIMS  – – Phase 2 CALLIPER Data Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Progressive Multiple Sclerosis, With Consistent Signals for Slowing Disability Progression Across Subgroups and Endpoints, Supporting Vidofludimus Calcium's Neuroprotective Potential and Nurr1 Activation Mechanism – – Long-Term Phase 2 EMPhASIS Data in Relapsing-Remitting Multiple Sclerosis Showed High Rates of Patients Remaining Free of Confirmed Disability Worsening and Favorable Long-Term Safety and Tolerability – – Top-Line Data from Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – NEW YORK , Nov. 13, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the three and nine months ended September 30, 2025, and provided a corporate update. "The third quarter was marked by our strong presence at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), during which we had the opportunity to highlight the clinical momentum of our lead asset, vidofludimus calcium (IMU-838), an orally available nuclear receptor-related 1 (Nurr1) activator, and its potential to transform the oral multiple sclerosis (MS) therapy landscape," stated Daniel Vitt, Ph.D.

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs. Vitt discussed the progress of Immunic's lead asset vidofludimus calcium, particularly its ongoing ENSURE Phase 3 trials for multiple sclerosis, which are fully enrolled and expected to report data at the end of 2026.

NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November: November 3-5: BIO-Europe. Daniel Vitt, Ph.D.

Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Dr Hella Kohlhof talked with Proactive about the company's research focus on multiple sclerosis (MS), highlighting how Immunic is aiming to address both the physical and mental health challenges faced by patients. Kohlhof explained the strong link between MS and mental health conditions such as depression and anxiety, noting that studies show around 30% of patients experience depression, while 20% experience anxiety.

NEW YORK , Oct. 1, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in October: October 4-7: UEGW 2025 – United European Gastroenterology Week. Immunic's R&D team will attend this conference in Berlin, Germany.

An unheralded New York–listed biotech is chasing one of neurology's biggest goals: a pill that not only tamps down the inflammatory flares of multiple sclerosis but also directly protects the brain from the slow, steady damage that leaves many patients disabled. Immunic Inc (NASDAQ:IMUX) is developing vidofludimus calcium, an oral medicine it says is “first-in-class” because it combines two mechanisms: one to reduce relapses and magnetic resonance imaging (MRI) lesions, and another aimed at shielding neurons from degeneration that accumulates even when flares are quiet.

Immunic Inc (NASDAQ:IMUX) has presented clinical trial data suggesting its oral therapy, vidofludimus calcium, could help slow disability in patients with progressive multiple sclerosis, a form of the disease that remains difficult to treat. The results were shared at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, one of the largest gatherings of neurologists and researchers in the field.